Sökning: onr:"20187407" >
Fracture Rate, Qual...
Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
-
Langdahl, Bente L. (författare)
-
Ljunggren, Östen (författare)
-
Benhamou, Claude-Laurent (författare)
-
visa fler...
-
Marin, Fernando (författare)
-
Kapetanos, George (författare)
-
Kocjan, Tomaz (författare)
-
Lespessailles, Eric (författare)
-
Napoli, Nicola (författare)
-
Nikolic, Tatjana (författare)
-
Petto, Helmut (författare)
-
Moll, Thomas (författare)
-
Lindh, Erik (författare)
-
visa färre...
-
(utgivare)
- 2016
- 2016
- Engelska.
-
Ingår i: Calcified Tissue International. - 0171-967X. ; 99:3, 259-271
Abstract
Ämnesord
Stäng
- We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(A (R)) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the > 18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.
Ämnesord
- Medical and Health Sciences (hsv)
- Clinical Medicine (hsv)
- Endocrinology and Diabetes (hsv)
- Medicin och hälsovetenskap (hsv)
- Klinisk medicin (hsv)
- Endokrinologi och diabetes (hsv)
Nyckelord
- Osteoporosis
- Observational study
- Teriparatide
- Fractures
- Quality of life
- Back pain
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Langdahl, Bente ...
-
Ljunggren, Östen
-
Benhamou, Claude ...
-
Marin, Fernando
-
Kapetanos, Georg ...
-
Kocjan, Tomaz
-
visa fler...
-
Lespessailles, E ...
-
Napoli, Nicola
-
Nikolic, Tatjana
-
Petto, Helmut
-
Moll, Thomas
-
Lindh, Erik
-
visa färre...
- Av lärosätet
-
Swepub_uni:_t